Vancouver, British Columbia – January 27, 2012 – Sirona Biochem Corp. (TSX-V: SBM) (the “Company”), a biotechnology company specializing in carbohydrate chemistry technology, announced today that the Company has received TSX Venture Exchange (the “TSXV”) acceptance to extend the term of the remaining 400,000 common share purchase warrants originally issued on February 24, 2010 (the ”February 2010 Warrants”) and the remaining 10,215,000 common share purchase warrants originally issued on October 23, 2010 (the “October 2010 Warrants”). Those warrants were issued as part of non-brokered private placements of its securities. The expiry dates of the February 2010 Warrants and October 2010 Warrants have been extended as follows:
February 24, 2010.
Number of Warrants: 400,000
Original Expiry Date of Warrants: February 24, 2012
New Expiry Date of Warrants: February 24, 2013
Exercise Price of Warrants: $0.40
October 23, 2010.
Number of Warrants: 10,215,000
Original Expiry Date of Warrants: October 23, 2012
New Expiry Date of Warrants: October 23, 2013
Exercise Price of Warrants: $0.20
All other terms of the February 2010 Warrants and October 2010 Warrants remain unchanged.
Please see the news release issued on January 29, 2010 and August 25, 2010 for further details.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, cancer vaccine antigens, cosmeceuticals and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of our carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business